JO
SCR

John Overdeck’s SIMCERE PHARMACEUTICAL GROUP, ADS SCR Stock Holding History

John Overdeck’s Portfolio SCR Stock Details SCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-10,398
Closed -$99K – 2353
2013
Q2 		$99K Buy
+10,398
New +$96.2K ﹤0.01% 1890

Other funds holding SCR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
EC
EJF Capital Arlington, Virginia $150M AUM 32.63% 1-Year Est. Return
HK
Horizon Kinetics New York $3.06B AUM 5.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

John Overdeck's SCR Position: Q3 2013 in Review

John Overdeck sold out of SIMCERE PHARMACEUTICAL GROUP, ADS (SCR) in Q3 2013, closing a stake of 10,398 shares — an estimated $99K sold.

John Overdeck first reported a position in SCR in Q2 2013 and held it in 1 quarter. The position peaked at $99K in Q2 2013. 20 funds tracked by Wall St. Rank hold SCR as of Q3 2013.

  • John Overdeck reported no remaining SIMCERE PHARMACEUTICAL GROUP, ADS position as of Q3 2013 after selling out during the quarter.
  • John Overdeck sold 10,398 SIMCERE PHARMACEUTICAL GROUP, ADS shares in Q3 2013, an estimated $99K.
  • John Overdeck first reported a position in SIMCERE PHARMACEUTICAL GROUP, ADS in Q2 2013 and held it in 1 quarter.
  • John Overdeck's SIMCERE PHARMACEUTICAL GROUP, ADS position peaked at $99K in Q2 2013.
  • 20 funds tracked by Wall St. Rank held SIMCERE PHARMACEUTICAL GROUP, ADS as of Q3 2013.

Based on Two Sigma Investments's 13F filing for Q3 2013, filed 14 Nov 2013.